BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36345011)

  • 21. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 23. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
    Li J; Wei L
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
    Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
    Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
    Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
    APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
    Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
    Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
    Zhou S; Parham DM; Yung E; Pattengale P; Wang L
    Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis.
    Qiao Y; Yuan F; Wang X; Hu J; Mao Y; Zhao Z
    Cancer Biomark; 2022; 35(2):227-243. PubMed ID: 36120772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
    Ghosh A; Ghosh A; Datta S; Dasgupta D; Das S; Ray S; Gupta S; Datta S; Chowdhury A; Chatterjee R; Mohapatra SK; Banerjee S
    Int J Cancer; 2016 Jun; 138(11):2732-44. PubMed ID: 26756996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
    Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
    BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
    Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
    BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of potential key genes in very early hepatocellular carcinoma.
    Wu M; Liu Z; Li X; Zhang A; Lin D; Li N
    World J Surg Oncol; 2019 May; 17(1):77. PubMed ID: 31043166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
    Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
    Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
    Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
    Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of 40S ribosomal protein S8 as a novel biomarker for alcohol‑associated hepatocellular carcinoma using weighted gene co‑expression network analysis.
    Bi N; Sun Y; Lei S; Zeng Z; Zhang Y; Sun C; Yu C
    Oncol Rep; 2020 Aug; 44(2):611-627. PubMed ID: 32627011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.